vs
RBB Bancorp（RBB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
RBB Bancorp的季度营收约是REGENXBIO Inc.的1.1倍（$32.3M vs $30.3M），RBB Bancorp净利率更高（31.5% vs -221.3%，领先252.8%），REGENXBIO Inc.同比增速更快（43.0% vs 12.6%），RBB Bancorp自由现金流更多（$42.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 7.0%）
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
RBB vs RGNX — 直观对比
营收规模更大
RBB
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出30.4%
12.6%
净利率更高
RBB
高出252.8%
-221.3%
自由现金流更多
RBB
多$95.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.3M | $30.3M |
| 净利润 | $10.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 39.5% | -190.0% |
| 净利率 | 31.5% | -221.3% |
| 营收同比 | 12.6% | 43.0% |
| 净利润同比 | 132.1% | -31.2% |
| 每股收益（稀释后） | $0.59 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RBBRGNX
| Q4 25 | $32.3M | $30.3M | ||
| Q3 25 | $32.6M | $29.7M | ||
| Q2 25 | $35.8M | $21.4M | ||
| Q1 25 | $28.5M | $89.0M | ||
| Q4 24 | $28.7M | $21.2M | ||
| Q3 24 | $30.3M | $24.2M | ||
| Q2 24 | $27.5M | $22.3M | ||
| Q1 24 | $28.2M | $15.6M |
净利润RBBRGNX
| Q4 25 | $10.2M | $-67.1M | ||
| Q3 25 | $10.1M | $-61.9M | ||
| Q2 25 | $9.3M | $-70.9M | ||
| Q1 25 | $2.3M | $6.1M | ||
| Q4 24 | $4.4M | $-51.2M | ||
| Q3 24 | $7.0M | $-59.6M | ||
| Q2 24 | $7.2M | $-53.0M | ||
| Q1 24 | $8.0M | $-63.3M |
毛利率RBBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率RBBRGNX
| Q4 25 | 39.5% | -190.0% | ||
| Q3 25 | 40.7% | -176.3% | ||
| Q2 25 | 36.1% | -296.3% | ||
| Q1 25 | 11.2% | 13.6% | ||
| Q4 24 | 17.6% | -242.1% | ||
| Q3 24 | 31.6% | -256.6% | ||
| Q2 24 | 35.6% | -251.3% | ||
| Q1 24 | 39.9% | -408.8% |
净利率RBBRGNX
| Q4 25 | 31.5% | -221.3% | ||
| Q3 25 | 31.2% | -208.3% | ||
| Q2 25 | 26.1% | -331.8% | ||
| Q1 25 | 8.0% | 6.8% | ||
| Q4 24 | 15.3% | -241.3% | ||
| Q3 24 | 23.1% | -246.3% | ||
| Q2 24 | 26.4% | -237.7% | ||
| Q1 24 | 28.4% | -405.4% |
每股收益（稀释后）RBBRGNX
| Q4 25 | $0.59 | $-1.30 | ||
| Q3 25 | $0.59 | $-1.20 | ||
| Q2 25 | $0.52 | $-1.38 | ||
| Q1 25 | $0.13 | $0.12 | ||
| Q4 24 | $0.26 | $-0.99 | ||
| Q3 24 | $0.39 | $-1.17 | ||
| Q2 24 | $0.39 | $-1.05 | ||
| Q1 24 | $0.43 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $212.3M | $230.1M |
| 总债务越低越好 | $119.9M | — |
| 股东权益账面价值 | $523.4M | $102.7M |
| 总资产 | $4.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.23× | — |
8季度趋势，按日历期对齐
现金及短期投资RBBRGNX
| Q4 25 | $212.3M | $230.1M | ||
| Q3 25 | $234.9M | $274.2M | ||
| Q2 25 | $191.9M | $323.3M | ||
| Q1 25 | $238.8M | $267.9M | ||
| Q4 24 | $257.7M | $234.7M | ||
| Q3 24 | $349.4M | $255.5M | ||
| Q2 24 | $252.8M | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务RBBRGNX
| Q4 25 | $119.9M | — | ||
| Q3 25 | $119.8M | — | ||
| Q2 25 | $119.7M | — | ||
| Q1 25 | $119.6M | — | ||
| Q4 24 | $119.5M | — | ||
| Q3 24 | $119.4M | — | ||
| Q2 24 | $119.3M | — | ||
| Q1 24 | $119.2M | — |
股东权益RBBRGNX
| Q4 25 | $523.4M | $102.7M | ||
| Q3 25 | $514.3M | $161.5M | ||
| Q2 25 | $517.7M | $213.7M | ||
| Q1 25 | $510.3M | $274.2M | ||
| Q4 24 | $507.9M | $259.7M | ||
| Q3 24 | $509.7M | $301.4M | ||
| Q2 24 | $511.3M | $348.3M | ||
| Q1 24 | $514.0M | $390.7M |
总资产RBBRGNX
| Q4 25 | $4.2B | $453.0M | ||
| Q3 25 | $4.2B | $525.2M | ||
| Q2 25 | $4.1B | $581.0M | ||
| Q1 25 | $4.0B | $490.9M | ||
| Q4 24 | $4.0B | $466.0M | ||
| Q3 24 | $4.0B | $519.1M | ||
| Q2 24 | $3.9B | $569.4M | ||
| Q1 24 | $3.9B | $629.2M |
负债/权益比RBBRGNX
| Q4 25 | 0.23× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.23× | — | ||
| Q4 24 | 0.24× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.23× | — | ||
| Q1 24 | 0.23× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $42.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 131.8% | -174.0% |
| 资本支出强度资本支出/营收 | 2.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.26× | — |
| 过去12个月自由现金流最近4个季度 | $73.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流RBBRGNX
| Q4 25 | $43.4M | $-52.3M | ||
| Q3 25 | $2.1M | $-56.0M | ||
| Q2 25 | $21.7M | $-49.3M | ||
| Q1 25 | $7.8M | $33.6M | ||
| Q4 24 | $58.5M | $-31.6M | ||
| Q3 24 | $24.5M | $-40.5M | ||
| Q2 24 | $11.7M | $-45.5M | ||
| Q1 24 | $4.8M | $-55.5M |
自由现金流RBBRGNX
| Q4 25 | $42.6M | $-52.8M | ||
| Q3 25 | $1.8M | $-56.5M | ||
| Q2 25 | $21.6M | $-49.7M | ||
| Q1 25 | $7.6M | $32.6M | ||
| Q4 24 | $57.7M | $-32.7M | ||
| Q3 24 | $24.2M | $-40.9M | ||
| Q2 24 | $11.5M | $-46.0M | ||
| Q1 24 | $4.7M | $-56.0M |
自由现金流率RBBRGNX
| Q4 25 | 131.8% | -174.0% | ||
| Q3 25 | 5.4% | -189.9% | ||
| Q2 25 | 60.2% | -232.8% | ||
| Q1 25 | 26.7% | 36.6% | ||
| Q4 24 | 201.0% | -154.2% | ||
| Q3 24 | 80.0% | -168.9% | ||
| Q2 24 | 42.0% | -206.2% | ||
| Q1 24 | 16.6% | -358.5% |
资本支出强度RBBRGNX
| Q4 25 | 2.5% | 1.7% | ||
| Q3 25 | 1.1% | 1.7% | ||
| Q2 25 | 0.3% | 1.8% | ||
| Q1 25 | 0.6% | 1.2% | ||
| Q4 24 | 2.7% | 5.1% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% | ||
| Q1 24 | 0.5% | 3.6% |
现金转化率RBBRGNX
| Q4 25 | 4.26× | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | 3.39× | 5.53× | ||
| Q4 24 | 13.34× | — | ||
| Q3 24 | 3.50× | — | ||
| Q2 24 | 1.61× | — | ||
| Q1 24 | 0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RBB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
